To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Resolute zotarolimus-elut… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Resolute zotarolimus-eluting stent in ST-elevation myocardial infarction (resolute-STEMI): A prespecified prospective register from the DAPT-STEMI trial

Journal article
Authors W. Postma
E. Fabris
M. Van der Ent
R. Hermanides
P. Buszman
C. Von Birgelen
S. Cook
Hans Wedel
G. De Luca
R. Delewi
F. Zijlstra
E. Kedhi
Published in Catheterization and Cardiovascular Interventions
ISSN 1522-1946
Publication year 2019
Published at Institute of Medicine, Department of Public Health and Community Medicine
Language en
Keywords acute myocardial infarction, antiplatelet therapy, coronary artery disease, drug-eluting stent, stent, optical coherence tomography, implantation, insights, outcomes, Cardiovascular System & Cardiology, esebro jh, 1987, circulation, v76, p142
Subject categories Cardiac and Cardiovascular Systems


Objectives To evaluate the safety and efficacy outcomes after primary percutaneous coronary intervention (pPCI) with second-generation Resolute (TM) zotarolimus-eluting stent (R-ZES) in patients enrolled in the DAPT-STEMI Trial (NCT01459627). Background R-ZES is one of the most used drug eluting stents worldwide. To date, the safety and efficacy data of this stent in setting of STEMI is limited. Methods The Resolute-STEMI is a prespecified prospective register that reports the safety and efficacy of R-ZES in setting of ST-Elevation Myocardial Infarction (STEMI) at 6 months for the following endpoints: a composite endpoint of all-cause mortality, any myocardial infarction (MI), any (unscheduled) revascularization, stroke and TIMI major bleeding, as well as target lesion failure and stent thrombosis (ST). Results From a total of 1,100 STEMI patients enrolled in the trial, 998 received a R-ZES. At 6 months the PE occurred in 42 (4.2%) patients. All-cause death, MI, revascularization, stroke and TIMI major bleeding was respectively 8 (0.8%), 9 (0.8%), 34 (3.4%), 2 (0.2%), and 4 (0.4%). The rate of target lesion revascularizations involving the culprit lesion was 1.1%. Target lesion failure was 1.5%. The rate of definite ST was 0.5%. The rate of both definite or probable ST was 0.7%. Conclusions The present analysis is the largest to date reporting short-term and mid-term clinical outcomes with the R-ZES stent in setting of STEMI. At 30 days and 6-months R-ZES has an outstanding safety and efficacy even in this high-risk category of patients.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?